2ˊ-脱氧鸟苷-5ˊ-一磷酸 | 902-04-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 中文名称: 2ˊ-脱氧鸟苷-5ˊ-一磷酸
• 中文别名: 2'-脱氧鸟苷-5'-一磷酸；去氧鸟粪核酸；2'-去氧鳥苷；5ˊ-一磷酸-2ˊ-脱氧鸟苷；2'-脱氧鸟苷-5'-单磷酸
• 英文名称: 2'-deoxyguanosine 5'-monophosphate
• 英文别名: 5'dGMP；dGMP；2'-Deoxyguanosine 5'-phosphate；[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 902-04-5
• 化学式: C₁₀H₁₄N₅O₇P
• 分子量: 347.224
• InChiKey: LTFMZDNNPPEQNG-KVQBGUIXSA-N

物化性质

• 密度：
  2.32±0.1 g/cm3(Predicted)
• 物理描述：
  Solid
• 碰撞截面：
  169.7 Ų [M+Na]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  182
• 氢给体数：
  5
• 氢受体数：
  9

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  2ˊ-脱氧鸟苷-5ˊ-一磷酸 在 cerium(III) chloride 、 HEPES buffer 、 氧气 作用下， 以 水 为溶剂， 生成 2'-脱氧鸟苷
  参考文献：
  名称：

  Hydrolysis of phosphomonoesters in nucleotides by cerium(IV) ions. Highly selective hydrolysis of monoester over diester in concentrated buffers

  摘要：

  在生理条件下，核苷酸中的磷酸单酯可被 CeIV 离子有效水解。在 pH 值为 7.2、温度为 50 °C 的条件下（[CeIV] = 10 mM），残基的半衰期约为 10 分钟。CeIV 离子水解磷酸单酯的速度快于水解磷酸二酯的速度。值得注意的是，使用浓缩缓冲溶液（TRIS 和 HEPES）可显著提高单酯水解对二酯水解的选择性。在 500 mM TRIS 缓冲溶液中，pdA 和 dAp 的水解速度分别是 d(ApA) 的 500 倍和 580 倍，而在 50 mM TRIS 缓冲溶液中的相应比率分别为 85 倍和 90 倍。在这些浓缩缓冲液中，CeIV 可以选择性地去除 d(pApA)的末端单磷酸。

  DOI：

  10.1039/a701481c
• 作为产物：
  描述：

  2'-脱氧鸟苷 在 high K_m 5'-nucleotidase 、 5’-肌苷酸 、 5’-三磷酸腺苷 作用下， 以 various solvents 为溶剂， 生成 2ˊ-脱氧鸟苷-5ˊ-一磷酸
  参考文献：
  名称：

  Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5′-phosphates by mammalian phosphotransferases

  摘要：

  Amdoxovir [(-)-beta-D-2,6-diaminopurine dioxolane, DAPD], the prodrug of dioxolane guanosine (DXG), is currently in Phase I/II clinical development for the treatment of HIV-1 infection. In this study, we examined the phosphorylation pathway of DXG using 15 purified enzymes from human (8), animal (6), and yeast (1) sources, including deoxyguanosine kinase (dGK), deoxycytidine kinase ;dCK), high K-m 5'-nucleotidase (5'-NT), guanylate (GMP) kinase, nucleoside monophosphate (NMP) kinase, adenylate (AMP) kinase, nucleoside diphosphate (NDP) kinase, 3-phosphoglycerate (3-PG) kinase, creatine kinase, and pyruvate kinase. In addition, the metabolism of C-14-labeled DXG was studied in CEM cells. DXG was not phosphorylated by human dCK, and was a poor substrate for human dGK with a high K-m (7 mM). Human 5'-NT phosphorylated DXG with relatively high efficiency (4.2% of deoxyguanosine). DXG-MP was a substrate for porcine brain GMP kinase with a substrate specificity that was 1% of dGMP. DXG-DP was phosphorylated by all of the enzymes tested, including NDP kinase, 3-PG kinase, creatine kinase, and pyruvate kinase. The BB-isoform of human creatine kinase showed the highest relative substrate specificity (47% of dGDP) for DXG-DP. In CEM cells incubated with 5 muM DXG for 24 h, 0.015 pmole/10(6) cells (similar to7.5 nM) of DXG-TP was detected as the primary metabolite. Our study demonstrated that 5'-nucleotidase, GMP kinase, creatine kinase, and NDP kinase could be responsible for the activation of DXG in vivo. (C) 2004 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bcp.2004.06.019

文献信息

• Method of treating cancer
  申请人：——

  公开号：US20030220241A1

  公开（公告）日：2003-11-27

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种前脂蛋白转移酶抑制剂的组合治疗癌症的方法，该方法包括向所述哺乳动物施用来自以下组中选择的至少两种治疗剂的量，所述组包括一种PSA共轭物和一种前脂蛋白转移酶抑制剂，所述治疗剂可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
• Synthesis, Characterization, and Conformational Analysis of DNA Adducts from Methylated Anilines Present in Tobacco Smoke
  作者：M. Matilde Marques、Luísa L. G. Mourato、M. Amélia Santos、Frederick A. Beland

  DOI：10.1021/tx950044z

  日期：1996.1.1

  to the arylamine nitrogen had a higher percentage of syn conformers. This observation was supported by theoretical simulation studies that indicated substantial percentages of low energy syn conformers, increasing with the substitution pattern in the order para < meta < ortho < ortho,para < ortho,meta. The results demonstrate that, although single-ring arylamines are considered weak carcinogens, their

  烟草烟雾中存在的一系列芳香胺（2-，3-和4-甲基苯胺，2,3-和2,4-二甲基苯胺）与DNA结合的能力已通过N-（酰氧基）芳基胺的反应进行了研究带有dG，dG核苷酸和DNA。通过光谱法和HPLC法将与dG和核苷酸反应的主要产物表征为N-（脱氧鸟苷-8-基）芳基胺。修饰DNA的HPLC和光谱分析表明相同的加合物。1 H和13 C NMR光谱的分析表明，含有在芳基胺氮上邻位的甲基取代基的加合物具有较高百分比的顺式构象异构体。这一观察结果得到理论模拟研究的支持，该研究表明低能同构异构体的百分比很高，并且随着取代模式的增加，其对位
• Compositions and methods for inhibiting expression of Nav1.8 gene
  申请人：Sah Dinah

  公开号：US20070105806A1

  公开（公告）日：2007-05-10

  The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.

  该发明涉及一种双链核糖核酸(dsRNA)，用于抑制Nav1.8基因(Nav1.8基因)的表达，包括具有核苷酸序列的反义链，其长度小于25个核苷酸，并且与Nav1.8基因的至少一部分基本互补。该发明还涉及包括dsRNA和药用可接受载体的药物组合物；使用该药物组合物治疗由Nav1.8基因表达引起的疾病的方法；以及在细胞中抑制Nav1.8基因表达的方法。
• Condensed pyrimidine derivatives as inhibitors of foic acid-dependent enzymes
  申请人：Stoicescu, Dan

  公开号：EP1754484A1

  公开（公告）日：2007-02-21

  The invention relates to compounds of the formula I, useful as inhibitors of folic acid-dependent enzymes, or pharmaceutically acceptable salts thereof: wherein: Z= O or S; B=-NR2-, -CH2NR2-, -CH2CH2NR2-, -CH2CHR7- or -CH2O-, wherein R2 is H or a C1-3 alkyl, alkenyl or alkynyl group, and R7 is H or a C1-3 alkyl or alkoxy group; A= and n, R3, R4 are defined as in the claims.

  该发明涉及公式I的化合物，作为叶酸依赖酶的抑制剂或其药用可接受的盐： 其中： Z= O或S; B=-NR2-, -CH2NR2-, -CH2CH2NR2-, -CH2CHR7-或-CH2O-， 其中R2为H或C1-3烷基，烯基或炔基，以及 R7为H或C1-3烷基或烷氧基; A= 以及n，R3，R4如索权中所定义。
• Probe for mass spectrometry of liquid sample
  申请人：——

  公开号：US20040142378A1

  公开（公告）日：2004-07-22

  Disclosed is a probe for mass spectrometry of liquid samples, which may effectively ionize the sample without adding a protic solvent to the mobile phase in the ionization method in mass spectrometry of liquid samples. The probe according to the present invention has a structure represented by the Formula [I]: R 2 -A-R  [I] (wherein R 1 represents an ionic functional group which becomes an ion in a solvent, R 2 represents a structure which can bind to other substance, and A represents an arbitrary spacer moiety).

  揭示了一种用于液体样品质谱的探针，可以在液体样品的质谱离子化方法中有效离子化样品，而无需向移动相中添加质子溶剂。根据本发明的探针具有以下式所表示的结构： R2-A-R [I] （其中R1代表在溶剂中成为离子的离子功能团，R2代表可以结合到其他物质的结构，A代表任意的间隔基团）。